Furthermore, we showed that inhibition of SEZ6L2 via treatment with an anti-SEZ6L2 antibody reduced drug resistance and TS formation, suggesting that anti-SEZ6L2 antibody therapy may be an option for reducing tumor relapse after chemotherapy in LUAD. The gene discussed is SEZ6L2; the disease is neoplasm.